Cargando…

Pharmacokinetics of a Single Dose of Azilsartan in Pediatric Patients: A Phase 3, Open-Label, Multicenter Study

INTRODUCTION: Azilsartan is an angiotensin II receptor blocker indicated for the treatment of patients with hypertension. The efficacy and safety of azilsartan are established in adults, but have not been evaluated in pediatric patients, nor has its pharmacokinetic profile been determined in pediatr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Enya, Kazuaki, Saji, Ben T., Kato, Takuya, Okamoto, Hiroyuki, Koumura, Emiko
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2018
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6096965/ https://www.ncbi.nlm.nih.gov/pubmed/30027478 http://dx.doi.org/10.1007/s12325-018-0754-5

Ejemplares similares

Safety and efficacy of azilsartan in paediatric patients with hypertension: a phase 3, single-arm, open-label, prospective study
por: Ito, Shuichi, et al.
Publicado: (2021)

Correction to: Safety and efficacy of azilsartan in paediatric patients with hypertension: a phase 3, single-arm, open-label, prospective study
por: Ito, Shuichi, et al.
Publicado: (2022)

Effect of azilsartan versus candesartan on morning blood pressure surges in Japanese patients with essential hypertension
por: Rakugi, Hiromi, et al.
Publicado: (2014)

Single-dose pharmacokinetics and safety of azilsartan medoxomil in children and adolescents with hypertension as compared to healthy adults
por: Webb, Nicholas J. A., et al.
Publicado: (2016)

Comparison of the efficacy and safety of azilsartan with that of candesartan cilexetil in Japanese patients with grade I–II essential hypertension: a randomized, double-blind clinical study
por: Rakugi, Hiromi, et al.
Publicado: (2012)

A Randomized, Single‐Center, Double‐Blind, Placebo‐Controlled Multiple‐Dose Phase 1 Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Imarikiren in Healthy Adult Nonelderly and Elderly Male Subjects
por: Matsuno, Kumi, et al.
Publicado: (2018)

Effects of Age, Sex, and Race on the Safety and Pharmacokinetics of Single and Multiple Doses of Azilsartan Medoxomil in Healthy Subjects
por: Harrell, Robert E., et al.
Publicado: (2015)

Effects of Food Intake on the Pharmacokinetics of Azilsartan Medoxomil and Chlorthalidone Alone and in Fixed‐Dose Combination in Healthy Adults
por: Dudkowski, Caroline, et al.
Publicado: (2016)

Safety and tolerability of azilsartan medoxomil in subjects with essential hypertension: a one-year, phase 3, open-label study
por: Handley, Alison, et al.
Publicado: (2016)

Efficacy and Safety of a Single-Pill Fixed-Dose Combination of Azilsartan and Amlodipine
por: Motozato, Kota, et al.
Publicado: (2016)

Critical evaluation of the efficacy and tolerability of azilsartan
por: De Caterina, Alberto R, et al.
Publicado: (2012)

Effects of azilsartan compared with telmisartan on insulin resistance in patients with essential hypertension and type 2 diabetes mellitus: An open-label, randomized clinical trial
por: Naruse, Mitsuhide, et al.
Publicado: (2019)

Improvement of Diurnal Blood Pressure Variation by Azilsartan
por: Okamura, Keisuke, et al.
Publicado: (2018)

Azilsartan: Current Evidence and Perspectives in Management of Hypertension
por: Pradhan, Akshyaya, et al.
Publicado: (2019)

Efficacy and Safety of Azilsartan and Telmisartan in Hypertensive Patients
por: Kumar, Alok, et al.
Publicado: (2021)

Effect of Azilsartan on Day-to-Day Variability in Home Blood Pressure: A Prospective Multicenter Clinical Trial
por: Miyoshi, Toru, et al.
Publicado: (2017)

Pharmacokinetic Drug–Drug Interactions Between Vonoprazan and Low-Dose Aspirin or Nonsteroidal Anti-inflammatory Drugs: A Phase 2, Open-Label, Study in Healthy Japanese Men
por: Sakurai, Yuuichi, et al.
Publicado: (2016)

Pharmacokinetics of Linezolid Dose Adjustment for Creatinine Clearance in Critically Ill Patients: A Multicenter, Prospective, Open-Label, Observational Study
por: Wang, Xipei, et al.
Publicado: (2021)

Phase I, multicenter, open‐label, dose‐escalation study of sonidegib in Asian patients with advanced solid tumors
por: Minami, Hironobu, et al.
Publicado: (2016)

Open‐Label, Dose‐Escalation, Phase 1 Study of Safety and Single and Multiple‐Dose Pharmacokinetics of Dichlorphenamide in Healthy Volunteers
por: Cohen, Fredric
Publicado: (2018)

Influence of Renal Impairment on the Pharmacokinetics of Afatinib: An Open-Label, Single-Dose Study
por: Wiebe, Sabrina, et al.
Publicado: (2016)

Azilsartan/chlorthalidone combination therapy for blood pressure control
por: Cheng, Judy WM
Publicado: (2013)

Optimization, characterization and in vitro/vivo evaluation of azilsartan nanocrystals
por: Ma, Jingjing, et al.
Publicado: (2017)

Single‐Center Evaluation of the Pharmacokinetics and Safety of the Angiotensin II Receptor Antagonist Azilsartan Medoxomil in Mild to Moderate Hepatic Impairment
por: Dudkowski, Caroline, et al.
Publicado: (2017)

Effect of renal function on the pharmacokinetics of fimasartan: a single-dose, open-label, Phase I study
por: Kim, Seokuee, et al.
Publicado: (2014)

Effect of renal impairment on the pharmacokinetics of prucalopride: a single- dose open-label Phase I study
por: Smith, William B, et al.
Publicado: (2012)

Neoadjuvant endocrine therapy with exemestane followed by response‐guided combination therapy with low‐dose cyclophosphamide in postmenopausal patients with estrogen receptor‐positive breast cancer: A multicenter, open‐label, phase II study
por: Sato, Nobuaki, et al.
Publicado: (2018)

Pharmacokinetics, safety, and tolerability of intravenous brivaracetam in pediatric patients with epilepsy: An open‐label trial
por: Farkas, Mark Kristof, et al.
Publicado: (2022)

Multicenter, Open-Label, Phase I Study of DSP-7888 Dosing Emulsion in Patients with Advanced Malignancies
por: Spira, Alexander, et al.
Publicado: (2021)

Differential pharmacology and benefit/risk of azilsartan compared to other sartans
por: Kurtz, Theodore W, et al.
Publicado: (2012)

Clinical utility of azilsartan–chlorthalidone fixed combination in the management of hypertension
por: Shuster, Jerrica E, et al.
Publicado: (2012)

Crystal structure of azilsartan methyl ester ethyl acetate hemisolvate
por: Li, Zhengyi, et al.
Publicado: (2015)

A multicenter, open-label, efficacy, pharmacokinetic, and safety study of adalimumab in Japanese patients with ankylosing spondylitis
por: Kobayashi, Shigeto, et al.
Publicado: (2011)

Safety and Pharmacokinetics of Intravenous Zanamivir Treatment in Hospitalized Adults With Influenza: An Open-label, Multicenter, Single-Arm, Phase II Study
por: Marty, Francisco M., et al.
Publicado: (2014)

Pharmacokinetics, Pharmacodynamics, and Safety of Nivolumab in Patients With Sepsis-Induced Immunosuppression: A Multicenter, Open-Label Phase 1/2 Study
por: Watanabe, Eizo, et al.
Publicado: (2020)

Efficacy and safety of different doses of azilsartan medoxomil in patients with hypertension: A protocol of a network meta-analysis
por: Zhang, Yan, et al.
Publicado: (2019)

A multicenter, randomized, open-label, active-comparator trial to determine the efficacy, safety, and pharmacokinetics of intravenous ibuprofen for treatment of fever in hospitalized pediatric patients
por: Khalil, Samia N., et al.
Publicado: (2017)

Infliximab for pediatric patients with Crohn’s disease: A Phase 3, open-label, uncontrolled, multicenter trial in Japan
por: Tajiri, Hitoshi, et al.
Publicado: (2018)

Infliximab for pediatric patients with ulcerative colitis: a phase 3, open-label, uncontrolled, multicenter trial in Japan
por: Tajiri, Hitoshi, et al.
Publicado: (2019)

A phase‐1, open‐label, single‐dose study of the pharmacokinetics of buparlisib in subjects with mild to severe hepatic impairment
por: Csonka, Denes, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_qod95cmrielbnjcq71cc1ep5bi